Filing Flows › Comparisons › PULM vs IBO
Pulmatrix vs Impact Biomedical: PULM and IBO compared
Pulmatrix is the larger company: $3K of revenue in its latest quarter (Q4 2024) against $3K for Impact Biomedical (Q2 2026). Impact Biomedical is growing faster (-57% against -100% a year earlier).
Where the money goes: PULM and IBO
Pulmatrix (PULM) · Q4 2024
Pulmatrix, Q4 2024: revenue $3K (-100% year over year), net loss $2.0M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
Impact Biomedical (IBO) · Q2 2026
Impact Biomedical, Q2 2026: revenue $3K (-57% year over year), net loss $700K, operating cash flow $470K. The chart follows the revenue to costs, profit and cash.
| Pulmatrix (PULM) | Impact Biomedical (IBO) | |
|---|---|---|
| Latest quarter | Q4 2024 | Q2 2026 |
| Revenue | $3K | $3K |
| Revenue growth, Y/Y | -100% | -57% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.0M | −$700K |
| Operating cash flow | −$1.3M | $470K |
Questions
Which is bigger, Pulmatrix or Impact Biomedical?
Pulmatrix is the larger company: $3K of revenue in its latest quarter (Q4 2024) against $3K for Impact Biomedical (Q2 2026).
Is Pulmatrix or Impact Biomedical growing faster?
Impact Biomedical is growing faster (-57% against -100% a year earlier).
More: Pulmatrix earnings · how Pulmatrix makes money · Impact Biomedical earnings · how Impact Biomedical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 21, 2025; 10-Q filed Aug 7, 2026). Fiscal quarters can end on different dates. Not investment advice.